289 related articles for article (PubMed ID: 32470392)
1. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A; Mathsyaraja H; Ibrahim AH; Freie B; Geuenich MJ; Cheng PF; Alibeckoff SP; Wu N; Hiatt JB; Basom R; Gazdar A; Sullivan LB; Eisenman RN; MacPherson D
Cancer Cell; 2020 Jul; 38(1):97-114.e7. PubMed ID: 32470392
[TBL] [Abstract][Full Text] [Related]
2. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
3. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
4. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
[TBL] [Abstract][Full Text] [Related]
5. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
6. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
[TBL] [Abstract][Full Text] [Related]
8.
Jia D; Augert A; Kim DW; Eastwood E; Wu N; Ibrahim AH; Kim KB; Dunn CT; Pillai SPS; Gazdar AF; Bolouri H; Park KS; MacPherson D
Cancer Discov; 2018 Nov; 8(11):1422-1437. PubMed ID: 30181244
[No Abstract] [Full Text] [Related]
9. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells.
Kimura M; Takenobu H; Akita N; Nakazawa A; Ochiai H; Shimozato O; Fujimura Y; Koseki H; Yoshino I; Kimura H; Nakagawara A; Kamijo T
Cancer Sci; 2011 May; 102(5):983-90. PubMed ID: 21276135
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
11. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
12. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
15. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
[TBL] [Abstract][Full Text] [Related]
17. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
18. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
19. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.
Schaffer BE; Park KS; Yiu G; Conklin JF; Lin C; Burkhart DL; Karnezis AN; Sweet-Cordero EA; Sage J
Cancer Res; 2010 May; 70(10):3877-83. PubMed ID: 20406986
[TBL] [Abstract][Full Text] [Related]
20. MYC, MAX, and small cell lung cancer.
Rudin CM; Poirier JT
Cancer Discov; 2014 Mar; 4(3):273-4. PubMed ID: 24596200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
